Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating

Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating — alphai